MEDICINES DISCOVERY CATAPULT LIMITED

• ◆

  5 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

1. MEDICINES DISCOVERY CATAPULT LIMITED 2016-03-01 → present
2. MEDICINES TECHNOLOGIES CATAPULT LIMITED 2015-12-23 → 2016-03-01

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

Beever and Struthers

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The forecasts indicate that the Group will have sufficient cash reserves for all its future anticipated activities. Based on this information, the Directors consider it appropriate to prepare the financial statements on a going concern basis.”

Group structure

1. MEDICINES DISCOVERY CATAPULT LIMITED · parent
   1. Medicines Discovery Catapult Services Commercial Limited 100% · England and Wales · Research and experimental development
   2. Medicines Discovery Ventures Limited 100% · England and Wales · Research and experimental development

Significant events

• “The National total body PET Imaging Platform (NPIP) has delivered its first scanner in London, with another to be launched in FY 25/26, and has stimulated funding for two new machines to be deployed in other areas of the UK.”
• “MDC is supporting the launch of the Dame Barbara Windsor Dementia Goals Programme, one of the government’s three national platforms in dementia, mental health, and obesity.”
• “The long-running multinational Psychiatry Consortium has been engaging widely with the sector, supported by industry and the Wellcome Trust, to shape its next ambitious phase.”
• “The PACE initiative, tackling Antimicrobial Resistance (AMR), has a portfolio of 11 projects and is recognised as a globally leading approach for supporting early-stage companies for this global threat.”
• “MDC's many services to the community across the UK were recognised in March, 2024 by the award of 'Non-Profit Life Sciences Enabler of the Year' by the Cambridge-based One Nucleus group and in March 2025 as 'Business Support of the Year' by the Northern region's Bionow group.”
• “MDC was awarded the ISO45001 accreditation for health and safety.”
• “This year has seen a spotlight on radiopharmaceutical therapy. Responding to the rapid advance of a growing class of therapeutics - radiopharmaceutical therapies (RPT) and theranostics - MDC has developed a significant pipeline and portfolio of projects...”
• “MDC has established a strategic partnership with Champions Oncology, aligning MDC's expertise in radiochemistry and pre-clinical imaging to Champions Oncology's advanced capability in pre-clinical oncology models.”
• “MDC announced a collaboration with United Kingdom National Nuclear Laboratory (UKNNL) to drive innovative approaches for new cancer treatments.”
• “This year saw the installation of the first scanner at Kings College Hospital in London, and its launch by The Secretary of State for Science, Innovation and Technology, Rt Hon Peter Kyle MP...”
• “With the MHRA, IDDC created a new regulatory roadmap for innovators developing new RNA therapies and vaccines to simplify the journey from research to commercialisation.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

9

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

5

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +4.8%

  £17,828,734 → £18,692,518

• Cash

  0%

  £38,991,109 → £38,998,712

• Net assets

  -2.6%

  £40,262,829 → £39,234,418

• Employees

  -1.3%

  151 → 149

• Operating profit

  -24.8%

  -£2,209,970 → -£2,756,958

• Profit before tax

  +12.4%

  -£1,079,179 → -£945,840

• Wages

  +5.1%

  £9,145,567 → £9,612,439

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers